162 related articles for article (PubMed ID: 23688272)
1. Transglutaminase inhibition as a possible therapeutical approach to protect cells from death in neurodegenerative diseases.
Iannaccone M; Serretiello E; De Vivo G; Martin A; Stefanile A; Titta F; Gentile V
Recent Pat CNS Drug Discov; 2013 Aug; 8(2):161-8. PubMed ID: 23688272
[TBL] [Abstract][Full Text] [Related]
2. Transglutaminases as possible therapeutic targets in neurodegenerative diseases.
Martin A; De Vivo G; Ricotta M; Iannuzzi M; Gentile V
Recent Pat CNS Drug Discov; 2010 Nov; 5(3):195-202. PubMed ID: 20636272
[TBL] [Abstract][Full Text] [Related]
3. Transglutaminase activity as a possible therapeutical target in neurodegenerative diseases.
Iannaccone M; Titta F; Serretiello E; De Vivo G; Martin A; Gentile V
Recent Pat CNS Drug Discov; 2013 Dec; 8(3):235-42. PubMed ID: 24286449
[TBL] [Abstract][Full Text] [Related]
4. Possible physiopathological effects of the transglutaminase activity on the molecular mechanisms responsible for human neurodegenerative diseases.
Iannaccone M; Titta F; Serretiello E; Monfregola M; Gentile V
Recent Pat CNS Drug Discov; 2014; 9(2):76-84. PubMed ID: 25386917
[TBL] [Abstract][Full Text] [Related]
5. Possible physiopathological roles of the transglutaminase activity in the etiopathogenesis of human neurodegenerative diseases.
Titta F; Iannaccone M; Martin A; Gentile V
Recent Pat CNS Drug Discov; 2014; 9(2):101-9. PubMed ID: 24924102
[TBL] [Abstract][Full Text] [Related]
6. Role of the transglutaminase enzymes in the nervous system and their possible involvement in neurodegenerative diseases.
De Vivo G; Di Lorenzo R; Ricotta M; Gentile V
Curr Med Chem; 2009; 16(36):4767-73. PubMed ID: 19929789
[TBL] [Abstract][Full Text] [Related]
7. Physio-pathological roles of transglutaminase-catalyzed reactions.
Ricotta M; Iannuzzi M; Vivo GD; Gentile V
World J Biol Chem; 2010 May; 1(5):181-7. PubMed ID: 21541002
[TBL] [Abstract][Full Text] [Related]
8. Transglutaminase-catalyzed post-translational modifications of proteins in the nervous system and their possible involvement in neurodegenerative diseases.
De Vivo G; Gentile V
CNS Neurol Disord Drug Targets; 2008 Oct; 7(4):370-5. PubMed ID: 18991665
[TBL] [Abstract][Full Text] [Related]
9. Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases.
Martin A; Giuliano A; Collaro D; De Vivo G; Sedia C; Serretiello E; Gentile V
Amino Acids; 2013 Jan; 44(1):111-8. PubMed ID: 21938398
[TBL] [Abstract][Full Text] [Related]
10. Transglutaminase-catalyzed reactions responsible for the pathogenesis of celiac disease and neurodegenerative diseases: from basic biochemistry to clinic.
Martin A; Romito G; Pepe I; De Vivo G; Merola MR; Limatola A; Gentile V
Curr Med Chem; 2006; 13(16):1895-902. PubMed ID: 16842200
[TBL] [Abstract][Full Text] [Related]
11. Transglutaminases - possible drug targets in human diseases.
Gentile V; Cooper AJ
Curr Drug Targets CNS Neurol Disord; 2004 Apr; 3(2):99-104. PubMed ID: 15078184
[TBL] [Abstract][Full Text] [Related]
12. Possible role of the transglutaminases in the pathogenesis of Alzheimer's disease and other neurodegenerative diseases.
Martin A; De Vivo G; Gentile V
Int J Alzheimers Dis; 2011 Feb; 2011():865432. PubMed ID: 21350675
[TBL] [Abstract][Full Text] [Related]
13. Transglutaminase-catalyzed crosslinking in neurological disease: from experimental evidence to therapeutic inhibition.
Hoffner G; André W; Vanhoutteghem A; Souès S; Djian P
CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):217-31. PubMed ID: 19811443
[TBL] [Abstract][Full Text] [Related]
14. Lysine-rich histone (H1) is a lysyl substrate of tissue transglutaminase: possible involvement of transglutaminase in the formation of nuclear aggregates in (CAG)(n)/Q(n) expansion diseases.
Cooper AJ; Wang J; Pasternack R; Fuchsbauer HL; Sheu RK; Blass JP
Dev Neurosci; 2000; 22(5-6):404-17. PubMed ID: 11111157
[TBL] [Abstract][Full Text] [Related]
15. Role of transglutaminase-catalyzed reactions in the post-translational modifications of proteins responsible for immunological disorders.
De Vivo G; Martin A; Trotta T; Gentile V
Inflamm Allergy Drug Targets; 2008 Mar; 7(1):24-9. PubMed ID: 18473897
[TBL] [Abstract][Full Text] [Related]
16. [Transglutaminase and neurodegenerative diseases].
Liu Z; Zeng J; Zeng S; Tang B; Wang J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Aug; 32(4):562-6. PubMed ID: 26252108
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms responsible for the involvement of tissue transglutaminase in human diseases: Celiac Disease.
Amantea G; Cammarano M; Zefferino L; Martin A; Romito G; Piccirillo M; Gentile V
Front Biosci; 2006 Jan; 11():249-55. PubMed ID: 16146729
[TBL] [Abstract][Full Text] [Related]
18. Transglutaminase is linked to neurodegenerative diseases.
Muma NA
J Neuropathol Exp Neurol; 2007 Apr; 66(4):258-63. PubMed ID: 17413316
[TBL] [Abstract][Full Text] [Related]
19. Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases.
Wilhelmus MM; van Dam AM; Drukarch B
Eur J Pharmacol; 2008 May; 585(2-3):464-72. PubMed ID: 18417122
[TBL] [Abstract][Full Text] [Related]
20. Critical role of transglutaminase and other stress proteins during neurodegenerative processes.
Caccamo D; Currò M; Condello S; Ferlazzo N; Ientile R
Amino Acids; 2010 Feb; 38(2):653-8. PubMed ID: 19960212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
